Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010

Elizabeth L. Yanik, Sonia Napravnik, Patrick Ryscavage, Joseph J. Eron, Susan L. Koletar, Richard D. Moore, Anne Zinski, Stephen R. Cole, Peter Hunt, Heidi M. Crane, James Kahn, William C. Mathews, Kenneth H. Mayer, Babafemi O. Taiwo

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18-53), 31 (19-56), 33 (20-59), and 350 (96-1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities.

Original languageEnglish
Pages (from-to)216-220
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume63
Issue number2
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Keywords

  • Antiretroviral therapy
  • Antiretroviral toxicity
  • Laboratory monitoring

Fingerprint Dive into the research topics of 'Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010'. Together they form a unique fingerprint.

  • Cite this

    Yanik, E. L., Napravnik, S., Ryscavage, P., Eron, J. J., Koletar, S. L., Moore, R. D., Zinski, A., Cole, S. R., Hunt, P., Crane, H. M., Kahn, J., Mathews, W. C., Mayer, K. H., & Taiwo, B. O. (2013). Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010. Journal of Acquired Immune Deficiency Syndromes, 63(2), 216-220. https://doi.org/10.1097/QAI.0b013e31828d69f1